Drugs / Florbetaben
Florbetaben
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03119558 | May 2016 → Aug 2018 | amyloidosis | Stanford University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01138111 | Jun 2008 → Dec 2011 | Alzheimer disease, senile plaque formation | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03744312 | Sep 2018 → Jul 2022 | Alzheimer disease | Columbia University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04576793 | Nov 2020 → May 2027 expected | Alzheimer disease | Columbia University | Recruiting | No outcome recorded |
| Phase 2 | NCT00928304 | Jun 2009 → Jan 2011 | Down syndrome, senile plaque formation | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00750282 | Aug 2008 → Nov 2010 | Alzheimer disease, senile plaque formation | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01020838 | Nov 2009 → Sep 2011 | Alzheimer disease | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05527288 | Jan → Sep 2021 | Alzheimer disease, mental disorder | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Florbetaben | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03744312 ↗ |
| Known as | 18F-Florbetaben | “Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.” NCT03119558 ↗ |
| Known as | BAY94-9172 | “Florbetaben, a 18F-labeled stilbene derivative (Neuraceq®, formerly known as BAY-949172), is a diagnostic radiopharmaceutical developed to visualize β-amyloid plaques in the brain.” PMID 30043115 ↗ Jul 20184“Florbetaben (BAY94-9172)” NCT01138111 ↗ “Florbetaben (BAY94-9172)” NCT01020838 ↗ “Florbetaben (BAY94-9172)” NCT00928304 ↗ “Florbetaben (BAY94-9172)” NCT00750282 ↗ |
| Known as | Neuraceq | “Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.” NCT03119558 ↗ |
| Modality | Diagnostic / imaging agent | “Florbetaben (¹⁸F) is a promising ¹⁸F-labelled amyloid-β-targeted PET tracer in clinical development.” PMID 21481640 ↗ Apr 2011 |
| Route | Intravenous | “single IV injection” NCT00928304 ↗ |